Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUPH NASDAQ:CTMX NASDAQ:PHVS NASDAQ:TRVI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$16.20-0.2%$15.77$7.28▼$16.88$2.08B1.411.12 million shs138,315 shsCTMXCytomX Therapeutics$2.98+1.5%$3.87$1.72▼$8.21$508.01M2.085.23 million shs519,885 shsPHVSPharvaris$32.20+2.3%$29.71$16.00▼$33.33$2.11B-2.35240,796 shs17,400 shsTRVITrevi Therapeutics$15.94+3.5%$14.09$5.41▼$16.25$2.27B1.041.43 million shs424,747 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals+1.37%+2.79%+6.15%+15.20%+99.26%CTMXCytomX Therapeutics-3.62%-1.68%-18.84%-33.41%+19.11%PHVSPharvaris-0.25%-0.44%+3.49%+20.21%+85.50%TRVITrevi Therapeutics+5.05%+13.32%+8.45%+44.06%+142.90%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$16.20-0.2%$15.77$7.28▼$16.88$2.08B1.411.12 million shs138,315 shsCTMXCytomX Therapeutics$2.98+1.5%$3.87$1.72▼$8.21$508.01M2.085.23 million shs519,885 shsPHVSPharvaris$32.20+2.3%$29.71$16.00▼$33.33$2.11B-2.35240,796 shs17,400 shsTRVITrevi Therapeutics$15.94+3.5%$14.09$5.41▼$16.25$2.27B1.041.43 million shs424,747 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals+1.37%+2.79%+6.15%+15.20%+99.26%CTMXCytomX Therapeutics-3.62%-1.68%-18.84%-33.41%+19.11%PHVSPharvaris-0.25%-0.44%+3.49%+20.21%+85.50%TRVITrevi Therapeutics+5.05%+13.32%+8.45%+44.06%+142.90%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPHAurinia Pharmaceuticals 2.33Hold$17.256.51% UpsideCTMXCytomX Therapeutics 2.91Moderate Buy$12.10306.72% UpsidePHVSPharvaris 2.69Moderate Buy$49.1852.74% UpsideTRVITrevi Therapeutics 3.00Buy$22.9043.63% UpsideCurrent Analyst Ratings BreakdownLatest CTMX, AUPH, TRVI, and PHVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2026PHVSPharvaris HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/20/2026TRVITrevi Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.005/19/2026CTMXCytomX Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$6.005/19/2026CTMXCytomX Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$6.005/15/2026AUPHAurinia Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B-) ➝ Hold (C+)5/13/2026PHVSPharvaris UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$74.005/13/2026PHVSPharvaris Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$75.00 ➝ $74.005/11/2026CTMXCytomX Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$17.00 ➝ $11.005/8/2026TRVITrevi Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$30.005/6/2026TRVITrevi Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$20.005/6/2026TRVITrevi Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$21.00(Data available from 6/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPHAurinia Pharmaceuticals$298.30M6.98$1.03 per share15.79$4.41 per share3.67CTMXCytomX Therapeutics$35.54M14.25N/AN/A$0.58 per share5.13PHVSPharvarisN/AN/AN/AN/A$4.71 per shareN/ATRVITrevi TherapeuticsN/AN/AN/AN/A$1.43 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPHAurinia Pharmaceuticals$287.20M$2.177.4720.24N/A99.97%26.62%19.65%7/30/2026 (Estimated)CTMXCytomX Therapeutics-$17.37M-$0.41N/AN/AN/A-166.40%-36.61%-28.02%8/6/2026 (Estimated)PHVSPharvaris-$198.79M-$3.18N/AN/AN/AN/A-67.56%-61.13%8/11/2026 (Estimated)TRVITrevi Therapeutics-$42.76M-$0.32N/AN/AN/AN/A-24.53%-23.37%8/6/2026 (Estimated)Latest CTMX, AUPH, TRVI, and PHVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026PHVSPharvaris-$0.8219-$0.70+$0.1219-$0.69N/AN/A5/7/2026Q1 2026AUPHAurinia Pharmaceuticals$0.18$0.25+$0.07$0.25$76.98 million$77.71 million5/7/2026Q1 2026CTMXCytomX Therapeutics-$0.14-$0.10+$0.04-$0.10$4.68 million$10.26 million5/5/2026Q1 2026TRVITrevi Therapeutics-$0.07-$0.09-$0.02-$0.09N/AN/A4/3/2026Q4 2025PHVSPharvaris-$0.69-$0.84-$0.15-$0.84N/AN/A3/17/2026Q4 2025TRVITrevi Therapeutics-$0.10-$0.06+$0.04-$0.06N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/ACTMXCytomX TherapeuticsN/AN/AN/AN/AN/APHVSPharvarisN/AN/AN/AN/AN/ATRVITrevi TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPHAurinia Pharmaceuticals0.085.555.01CTMXCytomX TherapeuticsN/A10.3810.38PHVSPharvarisN/A11.2411.24TRVITrevi TherapeuticsN/A24.7524.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPHAurinia Pharmaceuticals36.83%CTMXCytomX Therapeutics67.77%PHVSPharvarisN/ATRVITrevi Therapeutics95.76%Insider OwnershipCompanyInsider OwnershipAUPHAurinia Pharmaceuticals12.20%CTMXCytomX Therapeutics3.80%PHVSPharvarisN/ATRVITrevi Therapeutics18.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUPHAurinia Pharmaceuticals300128.60 million112.91 millionOptionableCTMXCytomX Therapeutics170170.19 million163.72 millionOptionablePHVSPharvaris3065.41 millionN/ANot OptionableTRVITrevi Therapeutics20141.98 million116.00 millionOptionableCTMX, AUPH, TRVI, and PHVS HeadlinesRecent News About These CompaniesTrevi Therapeutics Announces Upcoming June and July Event Schedule3 hours ago | globenewswire.comTrevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.June 4, 2026 | aol.comATrevi Therapeutics Shareholders Approve Stock and Governance ChangesJune 4, 2026 | tipranks.comTrevi Therapeutics, Inc. (TRVI) Analyst/Investor Day - SlideshowMay 15, 2026 | seekingalpha.comTrevi Therapeutics, Inc. (TRVI) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks TranscriptMay 12, 2026 | seekingalpha.comTrevi Therapeutics (TRVI) Gets a Buy from H.C. WainwrightMay 8, 2026 | theglobeandmail.comTrevi Therapeutics, Inc. (TRVI) Analyst/Investor Day TranscriptMay 7, 2026 | seekingalpha.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2026 Earnings Call TranscriptMay 7, 2026 | insidermonkey.comWhy Trevi Therapeutics (TRVI) Is Up 5.9% After Extending Its Cash Runway Into 2030May 6, 2026 | finance.yahoo.comTrevi Therapeutics, Inc. (TRVI) Q1 2026 Earnings Call TranscriptMay 6, 2026 | seekingalpha.comTrevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdatesMay 5, 2026 | globenewswire.comTrevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International ConferenceApril 30, 2026 | globenewswire.comTrevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026April 28, 2026 | globenewswire.comDid Trevi’s US$173 Million Raise and Share Expansion Just Reshape Trevi Therapeutics' (TRVI) Investment Narrative?April 24, 2026 | finance.yahoo.comTrevi Therapeutics to Participate in Upcoming May EventsApril 23, 2026 | globenewswire.comTrevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional SharesApril 20, 2026 | globenewswire.comWhat's going on with Trevi Therapeutics stock?April 17, 2026 | msn.comTRVI stock’s five-day rally pushes it to an all-time high – here’s what’s happeningApril 17, 2026 | msn.comTrevi Therapeutics: Late-Stage Transition Meets Execution RiskApril 17, 2026 | seekingalpha.comTrevi Therapeutics Prices Public Offering to Fund HaduvioApril 17, 2026 | tipranks.comMarketBeat’s Top 5 Rated Small-Cap Stocks...December 22, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCTMX, AUPH, TRVI, and PHVS Company DescriptionsAurinia Pharmaceuticals NASDAQ:AUPH$16.20 -0.03 (-0.15%) As of 10:59 AM Eastern This is a fair market value price provided by Massive. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.CytomX Therapeutics NASDAQ:CTMX$2.98 +0.05 (+1.54%) As of 10:59 AM Eastern This is a fair market value price provided by Massive. Learn more.CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Pharvaris NASDAQ:PHVS$32.20 +0.74 (+2.35%) As of 10:59 AM Eastern This is a fair market value price provided by Massive. Learn more.Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.Trevi Therapeutics NASDAQ:TRVI$15.94 +0.54 (+3.53%) As of 10:59 AM Eastern This is a fair market value price provided by Massive. Learn more.Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Gravity Check: Houston, SpaceX Has a Valuation Problem Okta’s AI Moment May Be Bigger Than Investors Realize Fox Captures The Living Room With $22B Roku Buy Dave & Buster’s Q1 Miss Raises the Stakes for Its Turnaround Plan Microsoft’s Xbox Problem Is Bigger Than a Console War Could a Tesla-SpaceX Merger Be Closer Than Investors Think? Flying Under the Radar: Lockheed Martin's $2.8B Stealth Setup Bread’s Comeback Is Real—But Is the Easy Money Gone? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
